A clinician, not a company, runs Germany's psilocybin compassionate use programme

Twenty-seven of the 28 compassionate use programmes on the German register are run by a pharmaceutical company. The psilocybin entry names a university institute and one psychiatrist.

No European application on file for the world's most advanced psilocybin programme

Britain's assessment machinery is built to start before a licence exists. It has nothing to start on. Twelve analysts took questions on Compass's last earnings call, and not one asked about Europe.

Europe already pays for clinic-administered psychiatry. Just not for psychedelics.

Lilly is recruiting depression patients in four EU countries while its psychedelic deal names no European milestone at all. The difference is not Europe. It is what Europe costs to enter for a scheduled drug, and what nobody has yet asked it to pay.

Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine

Eli Lilly bought AtaiBeckley for up to $3.8 billion and priced Europe at zero. Every regulatory milestone in the deal points at the FDA and the DEA. Not one points at the EMA.

Issue 6 / Week of 7-13 July 2026

Europe finally has a date to prescribe psilocybin: the first half of 2027. The trial behind it compared the drug to itself.

Issue 5 / Week of 30 June-6 July 2026

European psychedelic depression development just split into two camps. The dividing line is whether patients have to quit their antidepressants first.

Issue 4 / Week of 23-29 June 2026

LSD just posted the biggest depression number in psychedelic Phase 3 history. It did it under the one design choice that sank EPIsoDE.

Issue 3 / Week of 16–22 June 2026

Lead Story: Europe's most advanced psychedelic Phase 3 just got its hardest question

Issue 2 / Week of 9-15 June 2026

The psilocybin trials, the H1 review left out. Preview text: Two controlled European readouts complicate the real-world optimism. Here they are.

European Psychedelic Medicine: H1 2026 in Review

In six months Europe stopped being a bystander. Mostly.

Psychedelic Brief

Week of 2 to 8 June 2026

Why Psychedelic Brief Exists.